Navigation Links
Debiopharm Announces U.S. NDA Filing of Trelstar(R) 6-Month Formulation for Locally Advanced or Metastatic Prostate Cancer
Date:11/13/2008

LAUSANNE, Switzerland, Nov. 13 /PRNewswire/ -- Debiopharm Group (Debiopharm), a global independent biopharmaceutical development specialist focusing on serious medical conditions and particularly oncology, today announced that the New Drug Application (NDA) for the 6 month formulation of Trelstar(R) (triptorelin pamoate) has been accepted for filing by the United States (U.S.) Food and Drug Administration (FDA). Trelstar(R) is a luteinizing hormone releasing hormone (LHRH) agonist for the treatment of locally advanced or metastatic prostate cancer. Once approved, Trelstar(R) will be commercialised in the U.S. by Watson Pharmaceuticals, Inc.

"Last September we announced the filing of the product with the European Agencies, under the name Decapeptyl(R). We are proud to have accomplished the simultaneous filings of Trelstar(R) and Decapeptyl(R) in both the U.S. and Europe, it's a great achievement for us," said Rolland-Yves Mauvernay, president and founder of Debiopharm Group. "This demonstrates our ability to work effectively not only with different regulatory agencies, but also different partners. Furthermore, our FDA inspected research development and production facility, Debio R.P., will produce both products for global distribution."

The NDA for the 6 month formulation of Trelstar(R) is supported by data from a phase III study on the efficacy and safety of two consecutive injections of triptorelin 6-month formulation in 120 patients with advanced prostate cancer. The results showed that 97.5% of patients achieved castrate levels of serum testosterone 28 days after the first injection and that 93% of the patients maintained serum testosterone levels below castrate level (defined as < 1.735 nmol/L or 50 ng/dL) from week 8 to 48. These efficacy results are similar to those obtained previously with repeated administrations of the 1- and 3-month formulations of Trelstar(R), which are already marketed by Watson Pharmaceuticals, Inc.

About Deb
'/>"/>

SOURCE Debiopharm Group
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related medicine news :

1. Debiopharm and NanoCarrier Sign License and Supply Agreement for Dach-Platin Polymeric Micelle in Oncology
2. Ipsen and Debiopharm Extend Their Agreement for the Exclusive Commercialization of Decapeptyl(R) (triptorelin pamoate) in Europe and Certain Other Territories
3. In a Down Economy, Womens Health Company Announces Growth
4. R&Q Solutions, LLC Announces Launch to Serve Regions Medical Device Industry
5. WellPoint Announces Second Annual Innovation Event
6. CVS Caremark All Kids Can Announces the Opening of a Boundless Playground in Los Angeles to Serve Children of All Abilities
7. Sentry Data Systems Announces Healthcare Business Intelligence Technology Platform
8. HealthCentral Announces New Condition-Specific Ad Service to Offer Marketers the Highest Qualified Audiences
9. Wound Management Technologies, Inc. Announces FDA Clearance of 510k
10. GLEH LA, a Nonprofit Affiliate of Gay & Lesbian Elder Housing, Announces New Program Director
11. Governor Rendell Announces the Passing of Lt. Gov. Catherine Baker Knoll
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2014)... News) -- Health care workers in poor nations often ... safe from being infected with blood-borne viruses such as ... the study was conducted before the current Ebola outbreak ... confirmed in statistics released Monday by the World Health ... an "unprecedented" number of health care workers have lost ...
(Date:8/27/2014)... into Microtechnologies, is coordinating the microSCALE project ... on microtechnologies to tackle the problems of ... others. IK4-Ikerlan, Ceit-IK4, IK4-Tekniker, the Mondragon University ... on this project, which is being supported ... of the Government of the Basque Autonomous ...
(Date:8/27/2014)... This news release is available in German . ... need for medical agents to treat metastatic tumors. In case ... cancer that is often detected late, 95% of the patients ... amcure develops tumor therapeutic agents that might reduce this mortality ... has now received a total of EUR 5 million from ...
(Date:8/27/2014)... (PRWEB) August 27, 2014 When a friend invited ... was reluctant. But it was the beginning of a new way ... and very unhappy,” says Misty. “I knew I needed to turn ... though she may have been, Misty stuck with the program. “It ... I was so out of my comfort zone, but between the ...
(Date:8/27/2014)... 2014 Global leaders in robotics research, ... at the Minneapolis Marriott Northwest on September 16-17, 2014, ... robotics and autonomous systems at the Fourth Annual Robotics ... the wide variety of ways robotics is transforming industries ... nine different tracks of content. For this year’s Health ...
Breaking Medicine News(10 mins):Health News:Lack of Protective Gear Leaves Medics at Risk in Ebola Outbreak: Study 2Health News:Lack of Protective Gear Leaves Medics at Risk in Ebola Outbreak: Study 3Health News:Microtechnologies for driving forward mobility and human health 2Health News:Preclinical development of tumor therapeutic agent starts 2Health News:Whitby Fit Body Boot Camp Releases Gift Certificate for Two-Week Complimentary Access to Fitness Boot Camp 2Health News:Whitby Fit Body Boot Camp Releases Gift Certificate for Two-Week Complimentary Access to Fitness Boot Camp 3Health News:Robotics Alley, LifeScience Alley Partner on Health Care & Medical Device Track 2Health News:Robotics Alley, LifeScience Alley Partner on Health Care & Medical Device Track 3Health News:Robotics Alley, LifeScience Alley Partner on Health Care & Medical Device Track 4Health News:Robotics Alley, LifeScience Alley Partner on Health Care & Medical Device Track 5
... National Kidney FoundationMOUNTAIN VIEW, Calif., April 20 Satellite ... of kidney dialysis services and a major sponsor of ... will be honored by the National Kidney Foundation at ... 23 at Yoshi,s Jazz Club in San Francisco. Linda ...
... 20 The managing director of Publication CONNEXION, ... speak at the 45th Annual Drug Information Association ... be present a talk entitled "Effective Publication Practices" ... is a pharmaceutical industry five-day summit uniting professionals ...
... San Diego just moved closer to unlocking the ... mode" to "specialization mode." This computational biology work ... could lead to new ideas for curbing unwanted ... Nature Genetics , could also improve our ...
... and Women,s Hospital (BWH) and the Harvard-MIT Division ... way to deliver cancer drugs directly to tumors by ... pathway and deliver a higher concentration of medication to ... April 20, in an early online edition of the ...
... - Federal stimulus package provides needed economic boost to ... April 20 House Speaker Nancy Pelosi joined ... and Family Health Center to discuss the positive impact ... communities, which granted more than $10 million in federal ...
... few signs, imaging reveals patients at much greater risk ... "Silent" heart attacks occur more often than previously believed ... death, according to a Duke University Medical Center study. ... myocardial infarctions (UMIs), often go undetected because they don,t ...
Cached Medicine News:Health News:Renal Dietitian, Linda McCann, Receives 2009 Champion of Hope Award 2Health News:How cells change gears: New insights published in Nature Genetics 2Health News:How cells change gears: New insights published in Nature Genetics 3Health News:Brigham and Women's Hospital Researchers Demonstrate a More Direct Delivery of Cancer Drugs to Tumors 2Health News:Brigham and Women's Hospital Researchers Demonstrate a More Direct Delivery of Cancer Drugs to Tumors 3Health News:Brigham and Women's Hospital Researchers Demonstrate a More Direct Delivery of Cancer Drugs to Tumors 4Health News:Speaker Pelosi Visits Florida Health Center 2Health News:'Silent' Heart Attacks More Common Than Thought 2
(Date:8/27/2014)... --  Auxilium Pharmaceuticals , Inc. (NASDAQ: AUXL ... that certain members of the executive management team will ... held September 8-10, 2014 in New York ... and President, is scheduled to present an overview of ... ET on Wednesday, September 10, 2014. The ...
(Date:8/27/2014)... PARK, Calif. , Aug. 27, 2014 ... the U.S. Food and Drug Administration (FDA) to initiate ... in patients with complete cervical spinal cord injury.  The ... 1 clinical study of the product, and is designed ... AST-OPC1 in patients with complete cervical spinal cord injuries, ...
(Date:8/27/2014)... LONDON , Aug. 27, 2014 ... solutions, MarketResearch.com is pleased to announce the addition ... Devices Knowledge Center. The Medical Devices ... latest market research in the healthcare industry. Users ... from industry expert, Kalorama Information, published from 1998 ...
Breaking Medicine Technology:Auxilium Pharmaceuticals, Inc. To Present At The Morgan Stanley Healthcare Conference 2Auxilium Pharmaceuticals, Inc. To Present At The Morgan Stanley Healthcare Conference 3Asterias Biotherapeutics Receives U.S. FDA Clearance to Initiate Phase 1/2a Clinical Trial of AST-OPC1 in Patients with Cervical Complete Spinal Cord Injury 2Asterias Biotherapeutics Receives U.S. FDA Clearance to Initiate Phase 1/2a Clinical Trial of AST-OPC1 in Patients with Cervical Complete Spinal Cord Injury 3Asterias Biotherapeutics Receives U.S. FDA Clearance to Initiate Phase 1/2a Clinical Trial of AST-OPC1 in Patients with Cervical Complete Spinal Cord Injury 4Asterias Biotherapeutics Receives U.S. FDA Clearance to Initiate Phase 1/2a Clinical Trial of AST-OPC1 in Patients with Cervical Complete Spinal Cord Injury 5MarketResearch.com: New Medical Devices Research Reports Added to Kalorama Information Knowledge Center 2MarketResearch.com: New Medical Devices Research Reports Added to Kalorama Information Knowledge Center 3
... ADA,s 2009 Convention -- When Shawnae Jebbia won the Miss ... fairytale career. She appeared at events throughout the world, worked ... Shawnae,s world unexpectedly changed when she was diagnosed with hearing ... she had a difficult time understanding and accepting the sudden ...
... Oct. 29 Mettler-Toledo International Inc. (NYSE: MTD ) today announced ... , Sales in local currency declined by 12% in ... negative currency impact. , Net earnings per diluted ... third quarter of 2008. Adjusted EPS was $1.36, a 6% ...
Cached Medicine Technology:Former Miss USA Shawnae Jebbia Shines with Siemens Pure 2Former Miss USA Shawnae Jebbia Shines with Siemens Pure 3Mettler-Toledo International Inc. Reports Third Quarter 2009 Results 2Mettler-Toledo International Inc. Reports Third Quarter 2009 Results 3Mettler-Toledo International Inc. Reports Third Quarter 2009 Results 4Mettler-Toledo International Inc. Reports Third Quarter 2009 Results 5Mettler-Toledo International Inc. Reports Third Quarter 2009 Results 6Mettler-Toledo International Inc. Reports Third Quarter 2009 Results 7Mettler-Toledo International Inc. Reports Third Quarter 2009 Results 8Mettler-Toledo International Inc. Reports Third Quarter 2009 Results 9Mettler-Toledo International Inc. Reports Third Quarter 2009 Results 10Mettler-Toledo International Inc. Reports Third Quarter 2009 Results 11Mettler-Toledo International Inc. Reports Third Quarter 2009 Results 12Mettler-Toledo International Inc. Reports Third Quarter 2009 Results 13
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: